Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any Loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Century Sage Scientific Holdings Limited

世紀睿科控股有限公司

(Incorporated under the laws of the Cayman Islands with limited liability) (Stock Code: 1450)

CLARIFICATION ANNOUNCEMENT — INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2022

Reference is made to the announcement of Century Sage Scientific Holdings Limited (the "**Company**") dated 29 August 2022 to the interim results announcement for the six months ended 30 June 2022 (the "**2022 Interim Results**"). Unless the context requires otherwise, capitalised terms used in this announcement shall have the same meanings as those defined in the 2022 Interim Results.

Due to translation clerical error, the board of directors of the Company (the "**Board**") wishes to clarify that the first paragraph on page 2 of the Chinese version of the 2022 Interim Results shall be read as follows (with amendments underlined):

縱然面臨複雜的外部環境的不確定性,本集團加快業務拓展,增加營銷渠道,重 視人才梯隊的建設,大幅改善了經營情況。在中期期間,由於股份支付費用增 加、若干金融資產公允值損失及可換股債券遞延首日虧損攤銷,本集團於中期 期間錄得淨虧損約人民幣30.0百萬元,<u>較相應期間淨虧損約人民幣23.8百萬元有</u> <u>所增加</u>。然而,撇除上述項目的影響,本集團於中期期間錄得非香港財務報告準 則經調整淨溢利約人民幣5.0百萬元,相較於相應期間非香港財務報告準則經調 整淨虧損約人民幣5.7百萬元。有關按非香港財務報告準則計算的經調整淨溢利 /(虧損)詳情,請參閱本公告「非香港財務報告準則計量與最接近香港財務報告 準則計量的對賬」一段。

For the avoidance of doubt, the above amendments apply to the Chinese version of the 2022 Interim Results only. The corresponding paragraph in the English version of the 2022 Interim Results is correct and remain unchanged.

Save for the above clarification, all information in the Chinese and English versions of the 2022 Interim Results remains unchanged.

By Order of the Board Century Sage Scientific Holdings Limited Lo Chi Sun Chairman

Hong Kong, 30 August 2022

As at the date of this announcement, the executive Directors are Mr. Lo Chi Sum, Mr. Li Jun, Mr. Li Jinping and Ms. Zhao Hui Li, and the independent non-executive Directors are Mr. Cui Xiao Bo, Mr. Ma Zhan Kai and Dr. Yu Guo Jie.